Remote Digital Measurement of Facial and Vocal Markers of Major Depressive Disorder Severity and Treatment Response: A Pilot Study
- PMID: 34713091
- PMCID: PMC8521884
- DOI: 10.3389/fdgth.2021.610006
Remote Digital Measurement of Facial and Vocal Markers of Major Depressive Disorder Severity and Treatment Response: A Pilot Study
Abstract
Objectives: Multiple machine learning-based visual and auditory digital markers have demonstrated associations between major depressive disorder (MDD) status and severity. The current study examines if such measurements can quantify response to antidepressant treatment (ADT) with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine uptake inhibitors (SNRIs). Methods: Visual and auditory markers were acquired through an automated smartphone task that measures facial, vocal, and head movement characteristics across 4 weeks of treatment (with time points at baseline, 2 weeks, and 4 weeks) on ADT (n = 18). MDD diagnosis was confirmed using the Mini-International Neuropsychiatric Interview (MINI), and the Montgomery-Åsberg Depression Rating Scale (MADRS) was collected concordantly to assess changes in MDD severity. Results: Patient responses to ADT demonstrated clinically and statistically significant changes in the MADRS [F (2, 34) = 51.62, p < 0.0001]. Additionally, patients demonstrated significant increases in multiple digital markers including facial expressivity, head movement, and amount of speech. Finally, patients demonstrated significantly decreased frequency of fear and anger facial expressions. Conclusion: Digital markers associated with MDD demonstrate validity as measures of treatment response.
Keywords: Montgomery-Åsberg Depression Rating Scale; antidepressant treatment; computer vision; digital biomarker; digital phenotyping; machine learning; major depressive disorder.
Copyright © 2021 Abbas, Sauder, Yadav, Koesmahargyo, Aghjayan, Marecki, Evans and Galatzer-Levy.
Conflict of interest statement
At the time of the study, AAb, VY, VK and IG-L were employees of AiCure and held stock options in AiCure. CS, AAg, SM, and ME were employees of Adams Clinical, and CS was also an employee of Karuna Therapeutics. The authors declare that the study was jointly funded by AiCure, LLC and Adams Clinical, both of which may benefit from research reported in the manuscript and were involved in study design and execution. Adams Clinical conducted patient recruitment, enrollment, and clinical assessments. AiCure developed methods for digital phenotyping and provided software tools for remote collection of video data used. Both AiCure and Adams Clinical were involved in subsequent data analysis, interpretation, and presentation of findings.
Figures


Similar articles
-
Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.Psychiatry Clin Neurosci. 2015 Jan;69(1):34-42. doi: 10.1111/pcn.12214. Epub 2014 Aug 4. Psychiatry Clin Neurosci. 2015. PMID: 24965202 Clinical Trial.
-
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Encephale. 2009. PMID: 20004291 Clinical Trial. French.
-
Facial and Vocal Markers of Schizophrenia Measured Using Remote Smartphone Assessments: Observational Study.JMIR Form Res. 2022 Jan 21;6(1):e26276. doi: 10.2196/26276. JMIR Form Res. 2022. PMID: 35060906 Free PMC article.
-
Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.Cureus. 2024 Feb 10;16(2):e53987. doi: 10.7759/cureus.53987. eCollection 2024 Feb. Cureus. 2024. PMID: 38476783 Free PMC article. Review.
-
Escitalopram: a review of its use in the management of major depressive disorder in adults.CNS Drugs. 2010 Sep;24(9):769-96. doi: 10.2165/11204760-000000000-00000. CNS Drugs. 2010. PMID: 20806989 Review.
Cited by
-
Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants.Front Psychiatry. 2023 Jun 2;14:1135828. doi: 10.3389/fpsyt.2023.1135828. eCollection 2023. Front Psychiatry. 2023. PMID: 37333908 Free PMC article. Review.
-
Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings.Front Psychiatry. 2025 Jun 24;16:1571647. doi: 10.3389/fpsyt.2025.1571647. eCollection 2025. Front Psychiatry. 2025. PMID: 40630759 Free PMC article.
-
Measuring Health-Related Quality of Life With Multimodal Data: Viewpoint.J Med Internet Res. 2022 May 26;24(5):e35951. doi: 10.2196/35951. J Med Internet Res. 2022. PMID: 35617003 Free PMC article.
-
Racial and Ethnic Biases in Computational Approaches to Psychopathology.Schizophr Bull. 2022 Mar 1;48(2):285-288. doi: 10.1093/schbul/sbab131. Schizophr Bull. 2022. PMID: 34729605 Free PMC article. No abstract available.
-
Modern views of machine learning for precision psychiatry.Patterns (N Y). 2022 Nov 11;3(11):100602. doi: 10.1016/j.patter.2022.100602. eCollection 2022 Nov 11. Patterns (N Y). 2022. PMID: 36419447 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources